InsiderClue
Stocks · Health care · Services-Medical Laboratories

YD Bio Ltd

YDES Clue Score42
Cayman Islands Fiscal year ends December CIK 0002011674
$6.73 +16.23% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.73 −64.03% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 18 Aug 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue0.4Operating income−0.0Net income0.0EPS, diluted0.00Fiscal year 2024Revenue0.5 +45.8%Operating income−1.5Net income−1.4 −10,509.7%EPS, diluted−0.02Fiscal year 2025Revenue0.6 +16.9%Operating income−5.3Net income−8.3EPS, diluted−0.12
FY2023FY2024FY2025
Revenue 0.4 0.5 0.6
Growth +45.8% +16.9%
Operating income −0.0 −1.5 −5.3
Net income 0.0 −1.4 −8.3
Growth −10,509.7%
EPS, diluted 0.00 −0.02 −0.12
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Gross margin43.8%Operating margin−2.8%Net margin3.9%Free cash flow margin−16.0%Fiscal year 2024Gross margin30.4%Operating margin−286.5%Net margin−276.6%Free cash flow margin−254.3%Fiscal year 2025Gross margin28.1%Operating margin−883.3%Net margin−1,392.6%Free cash flow margin−1,346.6%
FY2023FY2024FY2025
Gross margin 43.8% 30.4% 28.1%
Operating margin −2.8% −286.5% −883.3%
Net margin 3.9% −276.6% −1,392.6%
Free cash flow margin −16.0% −254.3% −1,346.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−0.1Capital expenditure−0.0Free cash flow−0.1Fiscal year 2024Operating cash flow−1.2Capital expenditure−0.1Free cash flow−1.3Fiscal year 2025Operating cash flow−6.6Capital expenditure−1.4Free cash flow−8.0
FY2023FY2024FY2025
Operating cash flow −0.1 −1.2 −6.6
Capital expenditure −0.0 −0.1 −1.4
Free cash flow −0.1 −1.3 −8.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.1Shareholders’ equity0.0Fiscal year 2024Cash3.1Shareholders’ equity6.6Fiscal year 2025Cash6.0Shareholders’ equity−2.9
FY2023FY2024FY2025
Cash 0.1 3.1 6.0
Shareholders’ equity 0.0 6.6 −2.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.4 0.5 0.6
Growth +45.8% +16.9%
0.2 0.4 0.4
0.2 0.2 0.2
Growth +1.2% +7.8%
n/a 0.5 1.6
0.2 1.1 3.7
−0.0 −1.5 −5.3
Growth
0.0 −1.4 −8.3
0.0 0.0 −0.0
0.0 −1.4 −8.3
Growth −10,509.7%
Per share
0.00 −0.02 −0.12
0.00 −0.02 −0.12
Growth
64.7 64.7 66.7
64.7 64.7 66.7
Growth +0.0% +3.1%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 3 years on file.